G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced results from an immunologic analysis of Phase 2 study data showing that trilaciclib enhances both CD4 and CD8 T cell function in certain patients with metastatic triple negative breast cancer (mTNBC) …
Trending at Lumira Ventures
Nikhil Thatte Speaks at the BioTEC Biotechnology and Bioengineering Conference
Join Lumira Ventures, Principle, Nikhil Thatte for BioTEC’s Biotechnology and Bioengineering Conference November 13th , 2021 at 11:00 AM EST and November 14th, 2021 at 7:30PM EST. A weekend filled with insightful talks, exciting exhibitions, and innovative ideas as they …
Nikhil Thatte Speaks at the Innovation Economy Council Panel Discussion
Join Lumira Ventures, Principle, Nikhil Thatte for the Innovation Economy Council panel discussion this Wednesday, November 10th, 2021 on the state of Canada’s tech ecosystem and recent examples of how various exit scenarios can be a net benefit for Canada. …
Cyrano Therapeutics Announces the Appointment of John Kollins to its Board of Directors
Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy to restore smell and flavor function, today announced that it has appointed biopharmaceutical industry veteran John Kollins to its board of directors. Kollins is currently President and Chief Executive …
Iterion Therapeutics Announces Initiation of Phase 1/2 Clinical Trial to Study Tegavivint in Pediatric Cancers
Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the initiation of a Phase 1/2 clinical trial to investigate tegavivint as a potential treatment for pediatric cancers, including sarcomas, lymphomas and other solid tumors that …
Gerry Brunk Speaking at The Canadian Entrepreneurs in New England: Catalyst Forum 2021
Lumira Ventures Managing Director, Gerry Brunk will be speaking at the Catalyst Forum 2021: The Canadian Biotech Renaissance, at the Mainstage Session: The Financial Landscape Fueling the Growth. The event highlights everything from venture to private equity, as investors are …
Antiva Biosciences Closes $31 Million Series D Equity Financing
Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, today announced the closing of a $31 million Series D equity financing. The financing was supported by a syndicate of premier …
Peter van der Velden Speaking at the Life Sciences Ontario 12th Annual Policy Forum
Access to capital has been a perennial challenge for growing Canadian SMEs. The pandemic has raised awareness around many areas of life sciences and its importance to our economic and societal prosperity. Join Lumira Ventures General Partner and Managing Director, …
BioTheryX Receives IND Clearance from FDA to Proceed with Phase 1 Study of BTX-1188, a Molecular Glue, for the Treatment of Hematologic and Solid Malignancies
Enrollment for Phase 1 Clinical Trial to Commence by End of 2021 BioTheryX, Inc., a clinical-stage company focused on targeted protein degradation to create life-saving medicines, today announced that the U.S. Food and Drug Administration (FDA) cleared the company to …
Peter van der Velden Speaking on the Investment in BC Life Sciences Panel Discussion
Lumira Ventures General Partner and Managing Director, Peter van der Velden will be speaking Thursday, November 4th, 2021 at 3PM PT on the Investment in BC Life Sciences Panel Discussion with some of the most active investors in the BC …
LQT Therapeutics Announces the Appointment of Dr. Robert Booth to its Board of Directors
Company Strategically Strengthens its Fight Against Long QT Syndrome with Novel Kinase Drug Development Expertise Today, LQT Therapeutics, Inc. (LQTT) announced the addition of Dr. Robert Booth to its Board of Directors. Dr. Booth brings more than 30 years of biopharmaceutical …
Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV
Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), today announced the successful closing of a $75 million Series B-1 financing. The financing round was co-led by GordonMD Global …
BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer
BioTheryX, Inc., a clinical-stage company focused on targeted protein degradation to create life-saving medicines, today announced the appointment of Philippe Drouet as President and Chief Executive Officer of BioTheryX. “Philippe is an extremely talented biopharma executive with more than two decades of …
LAVA Medtech Acquisition Corp. Announces Closing of $115 Million Initial Public Offering Including Full Exercise of the Over-Allotment Option
LAVA Medtech Acquisition Corp. (the “Company”) today announced the closing of its initial public offering of 11,500,000 units at a price of $10.00 per unit, including 1,500,000 units pursuant to the full exercise of the underwriters’ over-allotment option. The offering was …
GenEp Raises $1.45 Million Seed Financing
GenEp, Inc., a biotechnology company developing therapies that address unmet needs in patients with epilepsy, announced today the closing of a $1.45 million seed financing. The financing was co-led by the UVA Licensing & Ventures Group Seed Fund, Angelini Lumira …